Rewrite the text in the first person. Adopt a laid-back tone. Keep the response under…
- User
Rewrite the text in the first person. Adopt a laid-back tone. Keep the response under 250 words. Separate paragraphs by using bullet points. Bold the first word of each paragraph.
Reference Text: A study finds that “gatekeeper” mutations make enzymes called kinases more active by destabilizing them in their inactive form, which may explain more aggressive cancer recurrence
Structure of the FGFR kinase showing the locations of the gatekeeper residue in the blue, hydrophobic spine in yellow, and ATP in cyan. Most drugs bind to the kinase in the same pocket as ATP. Structure of the FGFR kinase showing the locations of the gatekeeper residue in the blue, hydrophobic spine in yellow, and ATP in cyan. Most drugs bind to the kinase in the same pocket as ATP. Credit: Traaseth Lab/NYU More than 70 FDA-approved cancer drugs are kinase inhibitors, which work by blocking kinases—enzymes that add phosphate groups to molecules in the cell—and preventing the chemical activity necessary for signaling and growth in cancer cells. Kinase inhibitors can be very effective, but long-term, some patients experience aggressive recurrences that are more difficult to treat and resistant to the original drug.
A new study by New York University researchers, published this week in the journal Proceedings of the National Academy of Sciences, explains why cancers not only stop responding to kinase inhibitors but come back stronger, a finding that could inform which drugs oncologists use as a first-line treatment.
A leading cause of drug resistance—when cancer no longer responds to a kinase inhibitor— is the emergence of genetic mutations, particularly those in a region in the kinase called the “gatekeeper” residue. The gatekeeper is deeply embedded in the kinase and allows or prevents access to an even-deeper hydrophobic (or water-repelling) pocket.
Assistant
- So listen, I have been conducting this study on kinases that have shown that they are made by "gatekeeper" mutations. And no, these are not like the X-men mutations. These mutations make kinase more active by destabilizing them in their inactive form. This could explain more aggressive cancer recurrences.
- Nearly a hundred FDA-approved cancer drugs these days work by blocking kinases. While I admit that these inhibitors can be helpful for intermittent periods, long term, they can cause patients to have aggressive recurrences that often turn out to be more difficult to treat.
- A new study by, yours truly, helps shed some light on why cancers not only stop responding to kinase inhibitors but come back even tougher to deal with. This discovery could greatly affect the way that oncologists prescribe drugs to cancer patients.
- I have found that the biggest contributor to drug resistance from cancer formations is the emergence of the aforementioned genetic mutations, particularly those in a region called the "gatekeeper" residue. This residue can be found deeply embedded in the kinase, and it allows or prevents access to a water-repelling pocket.
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.